Despite the availability and effectiveness of highly active antiretroviral therapy and antipneumocystic prophylaxis, Pneumocystis jirovecii pneumonia (PCP) still occurs in industrialized nations. We performed a retrospective study of the patients who were hospitalized in our institution with the diagnosis of PCP from January 2003 to December 2005. There was no decline in the annual number of PCP cases during 36 months of study. Of 69 cases of PCP identified, less than half of patients were taking anti-retroviral medication, and only 13% were reported taking PCP prophylaxis. Twenty-six percent of our study population was newly diagnosed as having human immunodeficiency virus during the study period. The mortality rate was 10%. Renal insufficiency and renal failure were strongly associated with mortality in our study.
From the *Maimonides Medical Center, Brooklyn, NY; †Infectious Disease Associate, NW Ohio, Toledo, OH; and ‡Long Island College Hospital, Brooklyn, NY.
Reprints: Yu Shia Lin, MD, Maimonides Medical Center, 4802 Tenth Ave, Brooklyn, NY. E-mail: firstname.lastname@example.org.